Synonyms: Mulpleta® | S-888711 | S888711
lusutrombopag is an approved drug (Japan (2015), FDA (2018), EMA (2019))
Compound class:
Synthetic organic
Comment: Lusutrombopag is an orally bioavailable, nonpeptidyl, small molecule thrombopoietin (TPO) receptor agonist [3] that was developed by Shionogi in Japan. It was the second TPO receptor agonist to receive FDA approval in 2018 (avatrombopag was the first).
|
|
No information available. |
Summary of Clinical Use |
Lusutrombopag was first approved in Japan in 2015, to increase platelet count (and thus reduce bleeding risk) in patients with chronic liver disease-induced thrombocytopenia and who are scheduled for invasive surgery [2]. FDA approval for the same use was granted in July 2018 [1]. Lusutrombopag has completed Phase 2 clinical evaluation in patients with autoimmune thrombocytopenia (NCT01129024). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01129024 | An Open-label Safety Study of S-888711 | Phase 2 Interventional | Shionogi Inc. |